The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting

Journal of the American Medical Directors Association

Volumn 5, Issue 4, 2004, Pages 242-248

  Kasckow, Jhon W ^a,b,c   Mulchahey, J J ^d   Mohamed, S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d Phase 2 Discovery Inc   (United States)

Author keywords

Agitation; Atypical antipsychotics; Dementia; Side effects

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; AGITATION; AGRANULOCYTOSIS; BLOOD TOXICITY; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEGENERATIVE DISEASE; DELIRIUM; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GAIT DISORDER; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; MEDICAL DECISION MAKING; OPEN STUDY; ORTHOSTATIC HYPOTENSION; REVIEW; SEDATION; SEIZURE; SOMNOLENCE; TARDIVE DYSKINESIA; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED STATES;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; HUMANS; LONG-TERM CARE; NEURODEGENERATIVE DISEASES; PIPERAZINES; QUALITY OF LIFE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; RISPERIDONE; THIAZOLES; UNITED STATES;

EID: 4143100414     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70130-9     Document Type: Article

References (60)

1. Tariot PN. The older patient: The ongoing challenge of efficacy and tolerability. J Clin Psychiatry 1999;60(suppl 23):29-33.
2. Wynn Owen PA, Castle DJ. Late-onset schizophrenia. Drugs Aging 1999;15:81-89.
3. Chan Y, Parisier SE, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999;19:811-882.
4. Davidson J. Pharmacologic treatment. In: Busse EW, Blazer DG, eds. Textbook of Geriatric Psychiatry, 2nd ed. Washington, DC: American Psychiatric Press, 1996:359-379.
5. Nies A, Robinson DS, Friedman MJ, et al. Relationship between age and tricyclic antidepressant levels. Am J Psychiatry 1977;134:790-793.
6. Greenblatt DJ, Shader RJ. Benzodiazepine kinetics in the elderly. In: Usdin E, ed. Clinical Pharmacology in Psychiatry. New York: Elsevier, 1981:174-181.
7. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992;28:163-168.
8. Nelson JC, Atillasoy E, Mazure C, et al. Hydroxydesipramine in the elderly. J Clin Psychopharmacol 1998;8:428-433.
9. Young RC, Alexopoulos GS, Shamoian CA, et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin Pharmacol Ther 1984;35:540-544.
10. Cantillon M, Molchan SE, Little J, et al. Pharmacological and neuroendocrine probes in neuropsychiatric illness. In: Coffey CE, Cummings JL, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: APA Press, 1994.
11. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8:52S-56S.
12. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.
13. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719.
14. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic dose reduction in older psychotic patients. Arch Gen Psychiatry 1995;52:173-188.
15. Jeste DV, Lacro JP, Gilbert PL, et al. Treatment of late life schizophrenia with neuroleptics. Schizophr Bull 1993;19:817-830.
16. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
17. Meltzer HY, Fibiger HC. Olanzapine: A new atypical antipsychotic drug. Neuropsychopharmacology 1996;14:83-85.
18. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
19. Delected in proof.
20. Wagstaff AJ, Bryson HM. Clozapine. CNS Drugs 1995;4(suppl):370-400.
21. Chengappa KN, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995;8:12-15.
22. Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-1700.
23. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-131.
24. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996;57(suppl 3):39-45; discussion 49-50.
25. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999;7:132-138.
26. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998;6: 127-135.
27. Gareri P, Cortoneo A, Marchisio U, et al. Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr 2001;Suppl 1:173-182.
28. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
29. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
30. The Expert Consensus Panel for Agitation in Dementia. Treatment of agitation in older persons with dementia. Postgrad Med 1998;Spec No: 1-88.
31. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-304.
32. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. Mov Disord 2000;15:1230-1237.
33. Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997;9:594-597.
34. Cudkowicz ET, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-369.
35. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
36. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
37. Seeman P, Ohara K, Ulpian C, et al. Schizophrenia: Normal sequence in the dopamine D2 receptor region that couples to G-proteins. DNA polymorphisms in D2. Neuropsychopharmacology 1993;8:137-142.
38. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167.
39. Beasley CM Jr, Tollefson G, Tran P, et al. The olanzapine HGAD study group: Olanzapine versus placebo and haloperidol: Acute phase results of North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
40. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
41. Satterlee W, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 1997;31:534.
42. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-976.
43. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
44. Fontaine CS, Hynan LS, Koch K, et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003;64:726-730.
45. Cummings JL, Street J, Masterman D, et al. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002;13:67-73.
46. Ganger AS, Hanger HC. Olanzapine: Extrapyramidal side effects in the elderly. Aust N Z J Med 1999;29:371-372.
47. Graham JM, Sussman JD, Ford KS, et al. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease; a cautionary note. J Neurol Neurosurg Psychiatry 1998;65:774-777.
48. Saller CF, Salama AL, Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacol Bull 1993;112:285-292.
49. Allen RL, Cooney JM, Lawlor BA. The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994;9:415-417.
50. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1084.
51. Arvantis LA, Rak IW. Efficacy, safety and tolerability of 'Seroquel' (quetiapine) in elderly subjects with psychotic disorders. Schizophr Res 1997;24:196.
52. Matheson AJ, Lamb HM. Quetiapine: A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 2000;14:157-172.
53. Evatt ML, Jewart D, Juncos JL. Seroquel (ICI 204, 636) treatment of psychosis in parkinsonism. Mov Disord 1996;11:595.
54. Friedman J, Fernandez H, Jacques C. Quetiapine for the treatment of dopamimetic psychosis in Parkinson's disease [poster NR699]. Poster presentation, Annual Meeting of the American Psychiatric Association; May 15-20, 1999; Washington, DC.
55. Juncos JL, Evatt ML, Jewart RD, et al. Long term quetiapine treatment for psychosis in patients with Parkinson's disease who failed treatment with other atypical antipsychotics. ACNP Annual Meeting; Acapulco, Mexico; 1999a.
56. Targum SD, Abbott BA. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
57. Fernandez HH, Trieschmann ME, Burke MA, et al. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515.
58. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychoses in Parkinson's disease. Mov Disord 1999;14:484-487.
59. Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs 2002;16:645-652.
60. Berkowitz A. Ziprasidone for Elderly Dementia: A Case Series. San Francisco: American Psychiatric Association, 2003.